PD-1 Inhibitors Combined with Antiangiogenic Therapy with or Without Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Propensity Matching Analysis
Han Li,1,* Ke Su,1,* Lu Guo,2,* Yi Jiang,1 Ke Xu,1 Tao Gu,1 Jiali Chen,1 Zhenying Wu,1 Pan Wang,3 Xi Zhang,4 Yushan Yan,1 Siyuan Li,1 Xue Wu,1 Lei Han,5 Kun He,6 Lianbin Wen,7 Bo Li,4 Yunwei Han1 1Department of Oncology, The Affiliated Hospital of Southwest Medical University...
Main Authors: | Li H, Su K, Guo L, Jiang Y, Xu K, Gu T, Chen J, Wu Z, Wang P, Zhang X, Yan Y, Li S, Wu X, Han L, He K, Wen L, Li B, Han Y |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-07-01
|
Series: | Journal of Hepatocellular Carcinoma |
Subjects: | |
Online Access: | https://www.dovepress.com/pd-1-inhibitors-combined-with-antiangiogenic-therapy-with-or-without-t-peer-reviewed-fulltext-article-JHC |
Similar Items
-
Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review
by: Sacco R, et al.
Published: (2017-07-01) -
Transradial approach for transarterial chemoembolization of hepatocellular carcinoma in Egyptian patients: Initial study
by: Mohamed El-Gharib, et al.
Published: (2016-09-01) -
Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis
by: Jian Qin, et al.
Published: (2022-04-01) -
Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres® Microsphere Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Huge Hepatocellular Carcinoma
by: Xuhua Duan, et al.
Published: (2022-01-01) -
Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study
by: Peng Guo, et al.
Published: (2022-10-01)